Background. In metastatic testicular cancer patients treated with bleomycin, etoposide, and cisplatin (BEP) chemotherapy, bleomycin-induced pneumonitis is a well-known and potentially fatal side effect. We sought to determine the prevalence of lesions as signs of bleomycin-induced pulmonary changes on restaging computed tomography (CT) scans after treatment and to ascertain whether fibrosis markers were predictive of these changes. Patients and Methods. This prospective nonrandomized cohort study included metastatic testicular cancer patients, 18-50 years of age, treated with BEP chemotherapy. Restaging CT scans were examined for lesions as signs of bleomycininduced pulmonary changes by two independent radiologists and graded as minor, moderate, or severe. Plasma samples were collected before, during, and after treatment and were
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INTRODUCTION
Metastatic testicular cancer has a favorable prognosis; 5-year overall survival is more than 90% when the disease is treated with the current standard of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Bleomycin is considered an essential component of the regimen [1] . Although generally well-tolerated, bleomycin-induced pulmonary toxicity is observed in roughly 10% of the patients treated with BEP, with clinical symptoms such as dry cough, dyspnea, crackles during auscultation, abnormalities on chest radiography, and fever [2] . Bleomycin-induced pulmonary toxicity is predominantly a fibrotic lung disease; although its pathogenesis is not clear, the immune system appears to be involved [3, 4] . Bleomycin-induced pulmonary toxicity occurs during bleomycin treatment but can also develop after a treatmentfree interval of weeks to months [5] . In 1%-3% of the affected patients, this pulmonary toxicity is fatal [6] . The cumulative bleomycin dose is an important risk factor for bleomycininduced pulmonary toxicity, although a safe dose has not been established [7] . Other known risk factors are smoking, impaired renal function, and older age, but there is currently no test for predicting which patients will develop bleomycininduced pulmonary toxicity or a therapy to prevent it [8, 9] . The standard strategy in case of signs of bleomycin-induced pulmonary toxicity during treatment is to stop bleomycin administration. The change in diffusion capacity is used in several centers as a decision tool to terminate bleomycin administration, although these changes do not appear to be specifically caused by bleomycin [10] .
In previous studies, restaging computed tomography (CT) scans after completion of BEP chemotherapy for metastatic testicular cancer were reported to show signs suggesting bleomycin-induced pulmonary changes [11] [12] [13] . These radiologic changes may be a good surrogate endpoint for the development of bleomycin-induced pulmonary toxicity. However, because the effect of bleomycin on CT scans is observed only after completion of treatment, an upfront or early biomarker that identifies patients likely to develop bleomycin-induced pulmonary toxicity would be preferable. These patients could then be treated on a schedule without bleomycin. Anearly biomarker would supportthe decisiontostop weekly bleomycin administration.
Transforming growth factor-b1 (TGF-b1) is a cytokine involved in many physiological and pathological processes, including immune response, cell proliferation, angiogenesis, fibrosis, and oncogenesis [14] . TGF-b1 plays an important role in the development of bleomycin-induced pulmonary toxicity and fibrosis in animal models [15] [16] [17] . In patients treated with radiotherapy, or patients who have undergone stem cell transplantation, a relationship between TGF-b1 levels and treatment-induced pulmonary toxicity was found [18, 19] . Growth differentiation factor-15 (GDF-15) (also known as macrophage inhibitory cytokine-1) is a member of the TGF-b1 superfamily. GDF-15 is a product of activated macrophages and is involved in inflammatory processes [20] .The expression of GDF-15 is induced during the process of fibrosis and correlates with pulmonary function impairment in systemic sclerosis patients [21] . GDF-15 levels are also upregulated in many cancer types [22] . In addition, we evaluated the role of the generally known inflammation marker high-sensitivity C-reactive protein (hs-CRP).
In this study, we determined the prevalence of pulmonary changes assumed to be the result of bleomycin treatment on available restaging CT scans in metastatic testicular cancer patients. We also determined whether fibrosis markers TGFb1 and GDF-15 and the inflammation marker hs-CRP were predictive of these changes.
PATIENTS AND METHODS

Patients
We performed a prospective nonrandomized biomarker cohort study with the following eligibility criteria: patients aged 18-50 years with metastatic testicular cancer who were treated with BEP chemotherapy at the University Medical Center Groningen, The Netherlands. Exclusion criteria were a medical history of cardiovascular disease or a creatinine clearance ,60 mL per minute because primary assessments within the initial biomarker study were related to cardiovascular (2) parameters.The current study on bleomycin-induced pulmonary toxicity was performed within this biomarker study. Inclusion criteria forthis analysiswere aminimumof at leastthree bleomycin administrations (dose, 90 U.S. Pharmacopeia) and availability of a chest CTscan as part of the restaging evaluation after chemotherapy. Patients were treated with a standard regimen of 3 or 4 BEP chemotherapy courses, depending on International Germ Cell Consensus Classification prognosis group. During the first 6 days of each course, patients received daily antiemetic therapy with dexamethasone and ondansetron. The local ethics committee approved the study. All patients gave written informed consent.
CT Scans
Postchemotherapy restaging CT scans were assessed for lesions that are possibly the result of bleomycin treatment by two independent radiologists who were blinded for clinical phenotype. Patients were instructed to inhale during CTof the thorax. CTwas started 30 seconds after intravenous injection of contrast medium (55 mL Iomeron 350, Eisai Co., Tokyo, Japan, http://www.eisai.com). Scans were obtained in caudal-cranial direction from the deepest costophrenic pleural recesses to above the thorax aperture. For reconstruction, the following parameters were used: 3/1.5 mm on the Sensation-16 and Symbia T16 scanners and 2/1.5 mm on the S-64, Definition, and Biograph mCT scanners (kernel B40f) (used scanners: Siemens, Munich, Germany, http://www.siemens.com; Philips, Best, The Netherlands, http://www.philips.com; Toshiba, Zoetermeer, The Netherlands, http://www.toshiba-medical.eu; General Electric, Little Chalfont, Buckinghamshire, United Kingdom, http://www. gehealthcare.com). Radiologic criteria for lesions on restaging CT scan that were regarded as bleomycin-induced were that these lesions were newly developed since the start of BEP chemotherapy and could not be readily explained by other factors, such as metastases or infection. When available, the next CT scan (follow-up scan), obtained as part of the routine follow-up after completion of treatment, was assessed to judge whether the suspected bleomycin-induced pulmonary changes on the restaging CT scan had diminished or resolved. The type of lesion was described, and the lesion was scored as unifocal or multifocal; the location and number of lobes involved were noted.The extent of the radiologic lesions was graded as minor (involving only the outer third of the lung), moderate (involving both the outer and middle third of the lung, but not extending across the mediastinum), or severe (involving the whole width of the lung from periphery to mediastinum),according to Bellamy etal. [11] .
Measurement of Biomarkers
EDTA plasma samples were collected for all biomarkers before start of chemotherapy (day 1), for TGF-b1 on day 1 of every subsequent chemotherapy course, for GDF-15 and hs-CRP on day 8 of the third course, and for all measured biomarkers at 4 weeks after the end of chemotherapy (at follow-up). These time points were chosen because these were the dosing days of the bleomycin. EDTA blood samples were centrifuged at 3000 g at 4°C for 10 minutes, and plasma was stored at 220°C. Total TGF-b1 levels were analyzed in these samples after activation with hydrochloric acid using a human TGF-b1 Quantikine ELISA kit (R&D Systems, Abingdon, UK, https:// www.rndsystems.com/). GDF-15 levels were measured with the Human GDF-15 Quantikine ELISA kit (R&D Systems).The hs-CRP levels were analyzed by using a nephelometer.
Statistical Analysis
Differences in biomarker levels were determined between patients with and without pulmonary changes on CT scan and between patients with and without clinical bleomycin-induced pulmonary toxicity. We also analyzed differences between the groups based on the grade of the lesions on CT scan (none, 
RESULTS
Patients
Between May 2006 and June 2012, 78 patients were included in the biomarker study. In total, 5 patients were excluded from analysis because data were incomplete as a result of missed measurements or withdrawal of consent. Five patients received #2 BEP courses. Data from 66 patients were analyzed (Fig. 1, Table 1 ). Five of these 66 patients did not receive all initially planned bleomycin administrations because of clinical signs of bleomycin-induced pulmonary toxicity (n 5 3), development of bleomycin skin toxicity (n 5 1), and development of a pulmonary embolism (n 5 1). Time point refers to course number, followed by day number (e.g., 1.1 refers to course 1, day 1) b Mann-Whitney U tests. Abbreviations: C, 4 weeks after last course of chemotherapy; CT, computed tomography; GDF-15, growth differentiation factor-15; hs-CRP, high-sensitivity C-reactive protein; TGF-b, transforming growth factor-b; USP, U.S. Pharmacopeia.
Bleomycin-Induced Pulmonary Changes on CT Scan
Pretreatment staging CTscans of the chest and abdomen were obtained a median of 22 days (range, 1-78 days) before the start of chemotherapy. For evaluation of treatment response, restaging CT scans were obtained shortly after the last course of chemotherapy (median, 21 days [range, 5-112 days]). The CT scan during follow-up after completion of treatment was obtained a median of 175 days (range, 70-588) after the restaging CT scan. In 45 of 66 (68%) analyzed patients, radiological lesions of suspected bleomycin-induced pulmonary changes were seen on the restaging scan. Of these 45 patients, 37 were classified as having minor pulmonary changes and 8 as having moderate pulmonary changes (Fig. 2) . None of the changes were qualified as severe. Most pulmonary changes were multifocal and found in the basal parts of the lungs. No relationship was found between the cumulative dose of bleomycin and the development of suspected bleomycininduced pulmonary changes on the restaging CT scan. Renal function and smoking frequency did not differ between groups (Table 2) . On the available follow-up scans of patients suspected of having bleomycin-induced pulmonary changes (available in 38 of 45 patients [84%]), these lesions diminished in 14 patients (37%) and resolved in 24 patients (63%). Patient characteristics did not differ between these two groups (Table 3) .
In three patients for whom administration of bleomycin was halted because of clinical signs of bleomycin-induced pulmonary toxicity, the restaging CT scan showed moderate (n 5 1), minor (n 5 1), and no pulmonary changes (n 5 1).
Biomarker Plasma Levels Table 4 shows the biomarker plasma levels of all patients at clinically relevant time points. Median plasma levels before start of chemotherapy were 4,788 (range, 550-24,369) pg/mL for TGF-b1, 392 (range, 187-1,935) pg/mL for GDF-15, and 1.3 No significant differences in absolute or relative levels of TGF-b1, GDF-15, and hs-CRP at the measured time points were found between patients with no, minor, or moderate radiological bleomycin-induced pulmonary changes. In addition, no significant differences were found between patients with no or minor bleomycin-induced pulmonary changes and those with moderate pulmonary changes (Table 4) . However, more patients who developed pulmonary changes that were observed on CT scan (minor or moderate) had an increased TGF-b1 between day 1 of the first BEP course (before start of chemotherapy) and day 1 of the second course (86% vs. 60%; p 5 .047). In addition, GDF-15 levels on day 8 of the third course were higher in patients with moderate pulmonary changes on the CT scan than in patients with no or minor changes, although this difference was not statistically significant (7,246 pg/mL vs. 5,222 pg/mL; p 5 .087). All groups showed the same pattern of hs-CRP decrease during chemotherapy and an increase afterward.The biomarker levels of patients with clinical signs of bleomycin-induced pulmonary toxicity did not differ compared with those of other patients (Fig. 3) . In patients with pulmonary changesonfollow-upscansthathaddiminishedbutnotdisappeared (n 5 14) TGF-b1, GDF-15, and hs-CRP levels did not differ compared with the patient group in which pulmonary changes disappeared (n 5 24) ( Table 3) .
DISCUSSION
In this study, we determined the prevalence of pulmonary changes-assumed to be the result of bleomycin treatment-on available restaging CT scans after BEP chemotherapy in patients with metastatic testicular cancer. We also determined whether fibrosis markers TGF-b1, GDF-15, and inflammation marker hs-CRP were predictive for these changes. In 68% of these patients, radiological lesions on the restaging CTscan, interpreted as signs of bleomycin-induced pulmonary changes, were observed. However, bleomycin administration was halted prematurely in only 5% of the patients because of clinical presentation that was suspected as being the result of bleomycin-induced pulmonary toxicity during treatment. This discrepancy between clinical presentation of bleomycin-induced pulmonary toxicity and radiological signs of bleomycin-induced toxicity on CT scans is notable. Previous studies reported a much higher incidence of abnormalities on restaging CTscans as well, compared with the 10% of the patients who classically develop clinical signs of bleomycin-induced pulmonary toxicity [11] [12] [13] . However, these radiological abnormalities were not well documented and have not been reported in more recent clinical trials in which bleomycin is a component of the combination regimen for metastatic testicular cancer [23] .
The clinical relevance of radiological signs of bleomycininduced pulmonary abnormalities on restaging CT scans remains unclear. Most of these abnormalities on CT scans were without accompanying symptoms and resolved spontaneously based on subsequent CTscans obtained several months later during followup. Our research question was whether post-treatment radiological findings are accompanied by biochemical signs of active fibrosis which could potentially be used as early markers of the toxic effect of bleomycin on the lung.
In the current study, we did not find a difference in TGF-b1 levels between patients with and without radiological signs of bleomycin-induced pulmonary changes. However, patients who developed bleomycin-induced pulmonary changes on CT scan showed increased TGF-b1 levels from prechemotherapy to day 1 of the second course.This may indicate involvement of the TGF-b1 pathway in development of pulmonary abnormalities due to bleomycin administration.
The TGF-b1plasmalevels foundinour patientsat baseline had a broad range, as did these values in previous studies among healthy volunteers [24, 25] . Measured TGF-b1 levels in our patient group may also be tumor-derived rather than selectively the result of bleomycin-induced pulmonary changes [26] . However, no correlation between tumor markers in testicular cancer (a-FP, b-HCG, and LDH) and TGF-b1 levels before treatment was found. An interesting approach to solve this problem would be to assess TGF-b1 levels during bronchoalveolar lavage to assess only lung TGF-b1 levels [27] .
Although high levels of GDF-15 were present on day 8 of the third course, we found no differences in GDF-15 levels in patients with bleomycin-induced pulmonary changes on their CT scan compared with those without pulmonary changes. The increase in GDF-15 levels were larger in patients with moderate pulmonary changes on CT scans, but this difference was not significant. The number of patients with moderate changes (n 5 8) might have been too small to detect significant differences.
Although, hs-CRP could be an easily accessible biomarker for subclinical inflammation, levels did not differ between patients with and without bleomycin-induced pulmonary changes. Moreover, because of the concurrent administration of dexamethasone (antiemetic drug), hs-CRP is not a usable biomarker for bleomycin-induced pulmonary toxicity during chemotherapy.
Our study has several limitations. First, no high-resolution CT scans wereobtained inany patient, which precludes observations of interstitial pneumonitis. Second, we did not collect plateletpoor plasma, although TFG-b1 might have been released from platelets during collection and analyses of the samples [28] . TGF-b1 levels might have been falsely raised in our observation. However, this does not preclude comparison of TGF-b1 levels within our patient group. In addition, GDF-15 is also known as an apoptosis marker [20] , which might limit its distinctive value during cancer therapy. Nevertheless, it could be worth examining GDF-15 levels in a larger patient group with moderate pulmonary changes on CT scans after BEP chemotherapy. Abbreviations: GDF-15, growth differentiation factor-15; hs-CRP, high-sensitivity C-reactive protein; TGF-b1, transforming growth factor-b1.
CONCLUSION
Radiological pulmonary changes suspect for bleomycin-induced pulmonary toxicity are very common on restaging CT scans after treatment with BEP chemotherapy for metastatic testicular cancer, occurring in two thirds (68%) of the patients. Most of these radiological abnormalities appear to resolve on follow-up CTscans. TGF-b1, GDF-15, andhs-CRPdonotseemusableasearlybiomarkers for pulmonary bleomycin-induced toxicity or the corresponding radiological pulmonary changes.
